On December 31, 2024, Chengfan Medical announced the completion of nearly 50 million USD in Pre-A round financing. This round of financing was led by Panacea Venture (Ruifu Medical) and Shanghai Biomedical Fund, with existing shareholder Honghui Fund (HLC) continuing to support, along with multiple investment institutions including Everjoy Fortune, Wanwu Venture Capital, Delian Capital, and Lenovo Star participating together. The company's core research and development pipeline is expected to enter the clinical development stage in the USA and China in 2025.